5 Result(s)
-
Article
Integrating molecular diagnostics into anticancer drug discovery
Efforts to repeat the success of pioneering molecularly targeted cancer drugs, such as trastuzumab, for particular patient populations have been hampered by factors such as a lack of correlation between the mo...
-
Article
Open AccessTT-232: An Anti-tumour and Anti-inflammatory Peptide Therapeutic in Clinical Development
TT-232 is a structural derivative of the peptide hormone somatostatin with selective anti-proliferative and anti-inflammatory properties. It has a strong anti-tumour activity both in vitro and in vivo on a wide r...
-
Article
Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia
The putative anti-inflammatory and anti-nociceptive activity of the heptapeptide somatostatin analogue TT-232 (D-Phe-Cys-Tyr-D-Thr-Lys-Cys-Thr-NH2) was investigated in the rat and mouse, as well as its effect on ...
-
Article
New antitumor leads from a peptidomimetic library
A parallel combinatorial library of over 1600 compounds has been designed and synthesized for the development of new potential peptidomimetic protein tyrosine kinase (PTK) inhibitor leads. These peptidomimetic...
-
Article
New antitumor leads from a peptidomimetic library
A parallel combinatorial library of over 1600 compounds has been designed and synthesized for the development of new potential peptidomimetic protein tyrosine kinase (PTK) inhibitor leads. These peptidomimetic...
